Effect of Clostridium butyricum on Gastrointestinal Infections.

Biomedicines. February 2022;10(2):.

Tadashi Ariyoshi¹, Mao Hagihara², Motomichi Takahashi³, Hiroshige Mikamo⁴

¹ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ² Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ³ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.; ⁴ Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 480-1195, Aichi, Japan.

Abstract

Clostridium butyricum is a human commensal bacterium with beneficial effects including butyrate production, spore formation, increasing levels of beneficial bacteria, and inhibition of pathogenic bacteria. Owing to its preventive and ameliorative effects on gastrointestinal infections, C. butyricum MIYAIRI 588 (CBM 588) has been used as a probiotic in clinical and veterinary medicine for decades. This review summarizes the effects of C. butyricum, including CBM 588, on bacterial gastrointestinal infections. Further, the characteristics of the causative bacteria, examples of clinical and veterinary use, and mechanisms exploited in basic research are presented. C. butyricum is widely effective against Clostoridioides difficile, the causative pathogen of nosocomial infections; Helicobacter pylori, the causative pathogen of gastric cancer; and antibiotic-resistant Escherichia coli. Accordingly, its mechanism is gradually being elucidated. As C. butyricum is effective against gastrointestinal infections caused by antibiotics-induced dysbiosis, it can inhibit the transmission of antibiotic-resistant genes and maintain homeostasis of the gut microbiome. Altogether, C. butyricum is expected to be one of the antimicrobial-resistance (AMR) countermeasures for the One-health approach.

Keywords

Clostridioides difficile; Clostridium butyricum; Helicobacter pylori; gastrointestinal infection; gut dysbiosis;

Article Tools:

Medline

Email to me

Archives Highlights:

'Transmission Tracker - Dirofilaria'- a public dashboard to assess in real-time the temperature-bounded transmissibility of canine heartworm across Australia.
'Transmission Tracker - Dirofilaria' processes near real-time temperature records across Australia and allows users to enquire about historical and current weather suitability for canine heartworm transmission at any Australian postcode of their interest. This information allows veterinarians to access when, and for how long, heartworm may be transmitted at a specific location, assess the associated risk of infection, and advise on a patient-dependent dirofilariosis prevention plan for their canine patients and guardians.

Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis: A One Health Approach.
The overall seropositivity rate among tested dogs was 37.6%. Average test positivity rates in states with =0.5 tests per annum per 10,000 households were 35.4% (Texas) to 74.1% (Montana). For these states, average annual incidence per 10,000 households was as follows: Arizona (86.8), New Mexico (0.89), Nevada (0.78), California (0.75), Montana (0.63), Colorado (0.41), Oregon (0.41), Texas (0.38), Idaho (0.37), Wyoming (0.34), Utah (0.32), and Washington (0.26). Human incidence in California and Arizona between 2012 and 2022 was significantly correlated with dog incidence.

Companion animal veterinary personnel have occupational risk for tularemia and One Health role for tularemia prevention in Kansas.
Forty-three percent (47 of 109) of veterinarians reported diagnosing tularemia in cats and 13% (14 of 109) in dogs. Seven percent (8 of 109) of veterinarians reported having had tularemia. When performing procedures with a high risk of exposure, such as lancing abscesses in tularemia suspects, glove use was 100% but additional personal protective equipment was inconsistent, including eye protection (70%) and surgical face mask (59%).

Owner satisfaction and prognosis for return to work after pancarpal arthrodesis in working dogs in the United Kingdom: a retrospective study (2011-2020).
50% (5/10) owners stated their dog could perform normal duties; 4/10 (40%) could perform most duties with some allowances. 80% (8/10) owners rated the level of post-operative lameness as unaffected with a normal gait. 90% (9/10) owners were either very satisfied or satisfied with the outcome of the procedure, and 90% owners stated the financial investment was worthwhile.

Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.
The average duration of action of the 9.4 mg deslorelin implant was 790 ± 155 days (range 525-1140 days) with no significant difference in duration or efficacy depending on implantation sites. The 9.4 mg deslorelin implant causes pharmacological sterilization for about 2 years in female cats, is fully reversible, and caused no clinically relevant side effects when administered at both interscapular and periumbilical sites.